Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBEL3Q)

• Drug Name: GDC-0853 Drug Info
• Synonyms: Fenebrutinib

Indication

Disease Entry	ICD 11	Status	REF
Multiple sclerosis	8A40	Phase 3	[1]
Chronic idiopathic urticaria	EB00.1	Phase 2	[2]
Autoimmune disease	4A40-4A45	Phase 1	[3]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]

• Cross-matching ID:
  PubChem CID: 86567195
  CAS Number: CAS 1434048-34-6
  TTD Drug ID: DMBEL3Q

Molecule-Related Drug Atlas

Drug(s) Targeting Tyrosine-protein kinase BTK (ATK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibrutinib	DMHZCPO	Mantle cell lymphoma	2A85.5	Approved	[5]
Acalabrutinib	DM7GCVW	leukaemia	2A60-2B33	Approved	[6]
Zanubrutinib	DMJWRQP	Mantle cell lymphoma	2A85.5	Approved	[7]
Pirtobrutinib	DMRG1X3	Non-hodgkin lymphoma	2B33.5	Approved	[8]
ICP-022	DMU72KL	Chronic lymphocytic leukaemia	2A82.0	Phase 3	[9]
Tolebrutinib	DML19V6	Multiple sclerosis	8A40	Phase 3	[10]
CC-292	DMJR9H0	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[11]
BMS-986142	DMZB8AJ	Rheumatoid arthritis	FA20	Phase 2	[3]
LOU064	DME8O5K	Chronic idiopathic urticaria	EB00.1	Phase 2	[2]
BGB-3112	DMQCFSM	Follicular lymphoma	2A80	Phase 2	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tyrosine-protein kinase BTK (ATK)	TTGM6VW	BTK_HUMAN	Inhibitor	[3]

References

• [1] ClinicalTrials.gov (NCT04586023) Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS) (FENhance). U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] ClinicalTrials.gov (NCT01991184) A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.. U.S. National Institutes of Health.
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1948).
• [6] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [8] Targeting BTK in CLL: Beyond Ibrutinib. Curr Hematol Malig Rep. 2019 Jun;14(3):197-205.
• [9] Clinical pipeline report, company report or official report of InnoCare Pharma.
• [10] Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021 Sep;20(9):729-738.
• [11] Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther. 2013 Aug;346(2):219-28.
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)